Introduction
============

Although the main indications of antidepressants are psychiatric conditions, currently it is not uncommon for these drugs to be prescribed for non-psychiatric cases owing to their proven benefits in a wide range of therapeutic fields. These indications include urinary stress incontinence, irritable bowel syndrome, premature ejaculation, and treatment or pain \[[@b1-asj-2018-0237]\]. Surgical manipulation of subcutaneous tissues, bones, and ligaments may induce a significant postoperative pain \[[@b2-asj-2018-0237]\]. The first notion of using antidepressants in neuropathy was based on the treatment of depression to relieve pain. In the 1960s, an autonomous pain-relieving activity was detailed for tricyclic antidepressants (TCAs). Currently, antidepressants are listed as a first-line treatment for neuropathic pain and they are used in several aspects of spinal surgery. The treatment of neuropathic pain, which involves several heterogeneous factors, is an important subject in relation to spinal surgery due to the relatively high prevalence and complex characteristics of the type of pain.

Pain is an important factor that can affect surgical outcomes and overall patient satisfaction following surgery. Depression is known to be a cause of altered pain perception; increased perception of pain can worsen symptoms of depression. Additionally, patients who suffer from chronic pain, such as spinal cord injury (SCI) or chronic lower back pain (LBP), are more prone to develop depression \[[@b3-asj-2018-0237]\]. The incidence of pain is 65%--85% in patients with SCI, with half of these patients experiencing severe pain \[[@b4-asj-2018-0237]\]. Major depressive disorder (MDD) is reported in 25%--30% of patients with SCI \[[@b5-asj-2018-0237]\]. The mutual association between depression and pain results in a prolonged hospital stay and recovery time and poorer long-term outcomes \[[@b5-asj-2018-0237]\]. Previous studies have shown that the treatment of preoperative depression correlated with reductions in pain perception and disability \[[@b6-asj-2018-0237]\]. Furthermore, depression was found to be an independent predictor of postoperative delirium following surgery to the spine. It was concluded that postoperative delirium was a preventable cause of high cost and mortality rates in intractable cases relating to the spine \[[@b7-asj-2018-0237]\].

Aside from the benefits of antidepressants in terms of clinical results, spine surgeons need to be aware of the potential hazards of using antidepressants. For example, an increase in intraoperative bleeding and allogenic blood transfusion is associated with serotonergic antidepressants. Platelet function assay evaluation and assessment of the risk for transfusion are recommended prior to major procedures in cases in which the patient is taking antidepressants prior to surgery. Following surgery, tapering off drug may be considered according to resolving depression and decreased levels of postoperative pain \[[@b8-asj-2018-0237],[@b9-asj-2018-0237]\].

A thorough understanding of the use of antidepressant drugs is required by surgeons in terms of their advantages and disadvantages. In the literature, the benefits and risks of using antidepressants in spinal surgery have been reported frequently in recent years. To the best of our knowledge, this is the first comprehensive review regarding the advantages and disadvantages of prescribing antidepressants in the context of spinal surgery. Our aim is to review the literature and provide surgeons with evidencebased data to improve decision making regarding antidepressant drugs that directly impact the clinical outcomes of patients undergoing spine surgery.

Methods
=======

The PubMed/Medline, Scopus, Embase, and Central Cochrane Library were searched using a set of keywords in the form of the following code: "(antidepressant OR tca OR ssri) AND (spine OR spinal) AND (surgery)." All abstracts were double reviewed and checked by the authors according to the following preplanned list of inclusion criteria: (1) original clinical research relevant to the impact of antidepressant agents on the outcomes of spinal surgery or adverse events; (2) all antidepressant drugs were considered, including TCAs, selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, herbal drugs, or mirtazapine; (3) English abstracts; (4) at least 10 patients involved in the clinical study; and (5) articles published between January 2000 and February 2018. Our exclusion criteria were as follows: (1) clinical studies including \<10 patients; (2) review articles (secondary literature); (3) non-English full-text; and (4) basic science studies (preclinical studies and experimental bench work). The data are presented in two groups, interventional and observational studies, in [Table 1](#t1-asj-2018-0237){ref-type="table"} and [Table 2](#t2-asj-2018-0237){ref-type="table"}, respectively. We reported for each article the last name of the first author, month and year of publication, aim of the study, relevant results and/or conclusion, type of epidemiological study, and level of evidence. A short narrative review was then supplemented to emphasize the advantages and disadvantages of the use of antidepressant drugs in the field of spine surgery based on the available evidence provided by previously published work in this area of interest.

Results
=======

A total of 2,959 abstracts were identified following the use of the aforementioned set of keywords and following the removal of duplicates. As shown in [Fig. 1](#f1-asj-2018-0237){ref-type="fig"}, 17 articles were included in our review and are summarized in [Tables 1](#t1-asj-2018-0237){ref-type="table"} and [2](#t2-asj-2018-0237){ref-type="table"} for interventional \[[@b4-asj-2018-0237],[@b10-asj-2018-0237]-[@b16-asj-2018-0237]\] and observational \[[@b6-asj-2018-0237]-[@b9-asj-2018-0237],[@b17-asj-2018-0237]-[@b22-asj-2018-0237]\] studies, respectively. Only seven articles of the 17 (41.2%) were interventional studies, all of which were in the form of randomized controlled trials (RCTs). The remaining 10 articles (58.8%) were observational studies of different types (three cross-sectional, three case-control, and four cohort studies). A total of 53% (9/17) were prospective studies, while 35.3% (8/17) were retrospective studies; 58.8% (10/17) reported favorable outcomes for antidepressant agents, whereas 37.5% (6/17) did not show a clear benefit; one article was based on a survey conducted in the initial steps of an RCT. TCAs were involved in four of the 17 studies, serotonergic drugs (SSRIs/SNRIs) were involved in nine of the 17 studies. Only 11.8% (2/17) of the studies focused on cost. Of the 17 articles, three focused on the effect of antidepressants from a psychiatric perspective (to treat associated psychiatric comorbidity), while seven focused on antidepressant indication in the treatment of pain (without superadded depression or anxiety disorders). A total of five articles aimed to report major side effects (three for increased blood loss and two for possible osteoporosis). The median level of evidence provided by the included studies was 2.5, whereas seven of the 17 articles (41.2%) showed level I evidence in the interventional group. Of note, of the 17 articles, 13 articles were published between August 2015 and May 2017, whereas only three were published between November 2002 and January 2012.

Discussion
==========

Antidepressant drugs are used in many conditions in spine surgery and may be highly efficient if the advantages and disadvantages are thoroughly scrutinized by clinicians. We conducted a survey in Turkey regarding the trends of antidepressant prescription in neurosurgical practice and the results indicated that many clinicians either do not consider using antidepressants or have insufficient knowledge in terms of the indications of the drugs. Among 336 neurosurgeons enrolled in the survey, of whom 36% were spine surgeons, 47% did not routinely prescribe antidepressants, and 22% of the non-prescribers considered antidepressants to have no role in neurosurgery. Of the spine surgeons, 46.3% did not prescribe antidepressants \[[@b23-asj-2018-0237]\].

Although antidepressants can be a helpful tool to address challenging cases of spinal disease, there are conflicting opinions in terms of negotiating the risks that require clarification from the literature. These include the use of SSRI treatment in patients with osteoporosis, their effect on bone mineral density (BMD), intraoperative risk of bleeding and transfusion with serotonergic antidepressant use, pretreatment of depression for improving patient satisfaction, increased hospital costs, and longer hospital stays. In our experience, the tendency to prescribe antidepressants in tertiary medical care centers, such as research and university hospitals, is considered somewhat trivial among spine surgeons, as they have the ability to refer patients to psychiatrists if required. As a result of the ease of such referrals, many spine experts may omit the prescribing of antidepressants as an optional component in the conservative management of spine cases, which may lead to the masking of this useful group of invaluable drugs from practice. It is strongly encouraged that spine surgeons consider this area of pharmacotherapy to provide patients with additional benefits, provided they understand their potential adverse reactions. Evaluation of the risk/benefit ratio is the mainstay of clinical decision making. To the best of our knowledge, this is the first review on this topic that evaluates the literature in an evidencebased manner to guide clinicians while making decisions regarding the prescription of antidepressants for patients undergoing spine surgery or as a part of conservative treatment for non-surgical cases. Although evidence of bleeding tendency with serotonergic antidepressant agents appears solid in this review, evidence supporting the osteoporotic effect of antidepressants is clearly overstated.

The present study has limitations worthy of mention. First, only seven studies (of 17) were randomized clinical trials, whereas the remaining studies were observational (two prospective cohort, two retrospective cohort, four case-control, and two cross-sectional studies). Therefore, it is unlikely to address causality as the majority of the studies were observational. Measurement errors and selection bias were also potential limitations of the original articles, which may impact on interpretation. In crosssectional studies, no follow-up is expected. Additionally, the reliability of self-reported cognitive problems remain unclear compared with objective neuropsychologic assessment \[[@b24-asj-2018-0237]\]. Three of the studies mentioned a small sample size as a limitation \[[@b8-asj-2018-0237],[@b20-asj-2018-0237],[@b21-asj-2018-0237]\]. This review did not focus on a particular research question (i.e., testable null hypothesis) to run a meta-analysis for a specific scenario; instead, we reviewed all the relevant articles as each one, two, or maximum three articles had its own research question. Therefore, it would be either inefficient or invalid, in our opinion, to extract a net effect based on such scattered hypotheses. Running a meta-analysis requires homogeneity of all or most of the articles to detect the net effect, as well as its magnitude, direction, and statistical significance.

The future prospects, in this regard, aim toward conducting further RCTs comparing the efficacy of antidepressants as an adjunctive therapy to several drugs that are used more frequently in practice for neuropathic pain, namely pregabalin, gabapentin, or vitamin B6 (pyridoxine). It is anticipated that non-inferiority studies will offer a gateway for several antidepressant agents to expand their indications in cases of sciatica or failed back syndrome, before moving toward superiority trials. Another advance can be anticipated in establishing standardized conservative management protocols that emphasize the role of antidepressants, in order for spine surgeons to consider them among the plausible tools of pharmacotherapy, before declaring failure of conservative measures including medical treatment. Such strict protocols need to be adopted by international spine associations and committees, in the form of algorithms, to raise awareness of their profile and impact on patients that might be unclear for many surgeons. The financial burden of pushing for surgery in degenerative spine diseases may outweigh the cost of prescribing antidepressant agents in the right context.

Literature Review
=================

1. Neuropathic pain
-------------------

In the entire population, \>2% and 15% of the individuals of more than 40 years old suffer from neuropathy as a result of SCI, surgery, physical trauma to the nerve root, multiple sclerosis, or stroke. Several studies have been conducted to investigate treatment of neuropathic pain \[[@b3-asj-2018-0237],[@b18-asj-2018-0237]\].

In a randomized, double-blind, placebo-controlled phase III trial of 458 patients, 60 mg duloxetine monotherapy for Japanese patients with chronic LBP was performed. By measuring the Brief Pain Inventory score, the duloxetine-treated group showed a 2-point improvement at week 14 (*p*=0.001). The study group also showed significant improvements in secondary measures, including Brief Pain Inventory, Patients Global Impression of Improvement, Clinical Global Impression of severity, and Rolland-Morris Disability Questionnaire. Side effects, including somnolence, constipation, and nausea, were reported more frequently in the duloxetine group; however, they were not considered severe \[[@b11-asj-2018-0237]\].

As TCAs are likely to cause several side effects, combination therapy to lower the required dose of a TCA drug by adding an additional drug for neuropathic pain is common in the management of chronic sciatica. One study investigated chronic management of sciatica in the form of prescribing an additional drug (gabapentin) for neuropathic pain with a dose of 300 mg to 1.8 g to a preprescribed antidepressant drug amitriptyline (10--50 mg daily). In this prospective cohort study, which involved 77 patients, 56% had reductions in the Visual Analog Scale (VAS) score (*p*\<0.0001) and Oswestry Disability Index (ODI) score (*p*=0.008). A total of 82 side effects of 23 types, including amnesia, dizziness, confusion, fatigue, and ataxia, were reported in 53% of the patient population, whereas 34% withdrew from gabapentin in 1 week. Patients experiencing side effects benefited less from gabapentin in terms of reductions in VAS (*p*=0.08) and particularly ODI (*p*=0.01). Altered pain perception may have influenced these results \[[@b19-asj-2018-0237]\].

It is reported that 65%--85% of patients with SCI experience pain \[[@b12-asj-2018-0237]\]. TCA treatment for SCI-related neuropathic pain has been reported in the literature \[[@b25-asj-2018-0237]-[@b27-asj-2018-0237]\]. Furthermore, Richards et al. \[[@b4-asj-2018-0237]\] evaluated venlafaxine extended release (XR) for SCI-related pain and treatment of MDD. No reduction in neuropathic pain (*p*=0.815) was reported. Only patients suffering from nociceptive pain experienced a significant reduction (*p*=0.001), whereas patients with mixed pain (nociceptive+neuropathic) experienced less reduction. The patients were evaluated at baseline and at 6 and 12 weeks \[[@b4-asj-2018-0237]\]. In addition, the use of amitriptyline in SCI patients to improve pain and pain disability was reported as being ineffective by Cardenas et al. \[[@b10-asj-2018-0237]\] in 2002 according to their RCT. Although amitriptyline is widely used for chronic pain problems, this study did not support its use in SCI patients. Patient satisfaction, according to Life Scale in that study, was significantly higher in the active placebo group (*p*=0.004). Spasticity was more common in the amitriptyline group (*p*=0.0005) \[[@b10-asj-2018-0237]\].

2. Patient satisfaction and long-term outcomes
----------------------------------------------

Non-specific pain, disability, poor quality of life (QOL), and prolonged hospital stay are important determinants of postoperative patient satisfaction \[[@b6-asj-2018-0237],[@b7-asj-2018-0237],[@b13-asj-2018-0237],[@b16-asj-2018-0237]\].

Farrokhi et al. \[[@b16-asj-2018-0237]\] investigated pain and functional improvements with methylene blue (MB) injection on the soft tissue surrounding the fusion site following traumatic thoracolumbar fixation. Patients who underwent posterior pedicle screw fixation following thoracolumbar fractures received 1 mL of MB at a concentration of 0.5%. Subsequent pain and QOL were compared with those in a control group treated with normal saline by applying VAS and ODI. In the MB injection patient group, the mean VAS scores were significantly lower compared with those in the control group at 2 (*p*=0.001) and 6 (*p*=0.028) months postsurgery. The ODI score was higher at the 2- (*p*=0.001) and 6-month (*p*=0.016) interval follow-ups. That indicated improved functional QOL. Although a few patients admitted using additional analgesic drugs, a single dose of MB injection was considered adequate to render the pain bearable following surgery, and QOL showed notable improvement \[[@b16-asj-2018-0237]\]. Furthermore, Farrokhi et al. \[[@b13-asj-2018-0237]\] investigated the effects of postoperative MB injection on LBP and functional outcomes following lumbar open discectomy in 115 patients. Outcomes in the MB-injected group were evaluated and compared with those in the saline-treated group. At the 24-hour and 3-month follow-ups, the mean VAS scores for the MB group were significantly lower (*p*\<0.001 and *p*=0.019, respectively). LBP improvement was more marked in the MB group (*p*=0.023; 95% confidence interval, −1.37 to −0.10), whereas radicular pain did not differ (*p*=0.64). Functional QOL improvement was noted for both groups (*p*\<0.001) 3 months following the procedure \[[@b13-asj-2018-0237]\]. It was concluded that intradermal MB injection was an easy, quick, and effective procedure to reduce postoperational problems including LBP, radicular pain, and functional QOL. Intrathecal injection should be discarded to avoid neurological deficits \[[@b13-asj-2018-0237],[@b16-asj-2018-0237]\].

Depression is considered to be an aggravating factor for intractable pain. A retrospective study including 140 patients examined the outcomes of depression treatment prior to cervical spine surgery. Patients who underwent anterior cervical discectomy and fusion (ACDF) were evaluated using the Neck Disability Index (NDI) for functionality, Short Form-12 (SF-12) for mental health, and VAS for neck pain, prior to surgery and 3, 6, 12, and 24 months following surgery. None of the measures showed a significant difference between the patient group pretreated with antidepressants and the non-depressed control group (*p*=0.11 for NDI; *p*=0.63 for SF-12; *p*=0.80 for VAS). These results suggest that pretreatment eliminates the pain-altering effect of depression and improves clinical outcomes with higher patient satisfaction \[[@b6-asj-2018-0237]\].

In addition to increased pain and postoperative disability rates, depression is considered to be an independent risk factor for postoperative delirium. In a retrospective study of 923 adult patients with spine deformity, the delirium rate was 2-fold higher for depressed patients (10.59% versus 5.84%, *p*=0.01). Strong correlations between postoperative delirium and poor surgical outcomes, including high complication rates, prolonged hospital stay, increased health cost, and in-hospital mortality, have been reported \[[@b7-asj-2018-0237]\]. In a retrospective study, the outcomes 6 months after surgery in pretreated depression patients and nondepressed patients were reported to be similar \[[@b6-asj-2018-0237]\]. Overall, depression is a preventable cause of pain, pain-related disability, and postoperative delirium that leads to inferior outcomes for surgery. Therefore, pretreatment with antidepressants may be considered for favorable postoperative outcomes in terms of pain and delirium \[[@b6-asj-2018-0237],[@b7-asj-2018-0237],[@b13-asj-2018-0237],[@b16-asj-2018-0237]\].

3. Intraoperative bleeding and perioperative transfusion risk
-------------------------------------------------------------

Several studies have shown an increased risk for intraoperative bleeding with perioperative serotonergic antidepressant treatment \[[@b8-asj-2018-0237],[@b9-asj-2018-0237],[@b22-asj-2018-0237],[@b28-asj-2018-0237],[@b29-asj-2018-0237]\]. SSRIs induce serotonin depletion in platelets with reuptake inhibition, leading to impaired aggregation and vasoconstriction \[[@b8-asj-2018-0237],[@b9-asj-2018-0237],[@b22-asj-2018-0237]\].

In a study performed by Sayadipour et al. \[[@b9-asj-2018-0237]\] in 2012, intraoperative blood loss was reported for the study group of patients taking antidepressants compared with those not taking (control group), who underwent ACDF, posterior cervical fusion, combined anterior-posterior cervical fusion, anterior lumbar interbody fusion, posterior lumbar fusion (PLF), or combined anterior-PLF. The results indicated that the mean blood loss was 23% higher in those taking antidepressants than in the control group (298 versus 241 mL, *p*=0.01). The blood loss was profound in anterior-PLF surgeries with 2.5-fold higher rates than in the matched group. Among the antidepressants, SSRI/SNRI drugs led to more marked bleeding (334 versus 241 mL, *p*=0.015). According to the surgery type, the blood loss difference in PLF patients between the study and control groups was more than in other subgroups (560 versus 457 mL, *p*=0.032). Patients prescribed bupropion who underwent PLF showed higher blood loss than the control group (708 versus 457 mL, *p*=0.023) \[[@b9-asj-2018-0237]\]. This evidence was corroborated by Schadler \[[@b8-asj-2018-0237]\] in 2017, who reported a 34% increase in the blood loss with SSRI intake in patients who underwent single-level fusion surgery of the lumbar spine (*p*=0.015). However, SNRIs have not been proven to be significantly related to prediction of blood loss due to their low affinity to serotonin transporters (*p*=0.375). Female gender was also a strong indicator for the risk of blood loss (odds ratio \[OR\], 5.952; *p*=0.029). In addition, SSRIs have been associated with perioperative allogeneic blood transfusion (OR, 4.55; *p*=0.029) \[[@b8-asj-2018-0237]\].

Similar results were reported by Sajan et al. \[[@b22-asj-2018-0237]\] in 2016. Preoperative SSRI administration increased the probability of hemostatic transfusion by 2-fold, whereas SNRIs and other antidepressants were statistically insignificant. However, SNRIs had similar trends to those of SSRIs \[[@b22-asj-2018-0237]\]. Switching patients to antidepressants that do not work via serotonin reuptake inhibition may be considered prior to a major surgical procedure. A Platelet Function Assay (PFA) is the only effective test for risk assessment due to serotonin reuptake inhibitory effect on platelet function. Therefore, PFA evaluation and assessment of risk for transfusion are recommended prior to large surgical procedures. Tapering off the drug may be considered according to resolving depression following surgery and reduced pain levels. Of note, cytochrome P450 enzymes can be inhibited by SSRIs when concomitantly used with nonsteroidal anti-inflammatory drugs. Those concerns warrant further investigations by spine surgeons for each case to plan accordingly \[[@b9-asj-2018-0237]\].

4. Bone mineral density
-----------------------

Life expectancy is progressively increasing; therefore, osteoporosis is witnessed in association with depression in the elderly. Dual treatment of these two diseases is crucial in order to improve the QOL and reduce both comorbidity and mortality \[[@b21-asj-2018-0237]\]. SSRI treatment has been commonly associated with low BMD, albeit controversially in the literature.

Rauma et al. \[[@b17-asj-2018-0237]\] conducted a study that examined the relationship between SSRI treatment and BMD in men. They showed a negative correlation between BMD and SSRI treatment only in lower-weight men, depending on the bone site. The use of antidepressants, as indicated by recurrent MDD, was associated with lower spine BMD (*B*=−0.047) \[[@b17-asj-2018-0237],[@b21-asj-2018-0237]\].

Cortisol and catecholamine release, induced by chronic stress, may be responsible for bone loss in patients with depression. Recurrent MDD was associated with lower BMD scores for the forearm (6.5%) and total body (2.5%) compared with men without MDD records. Moreover, lower spine BMD was noted with recurrent MDD (4% lower). Although the line between MDD and antidepressant treatment was unclear, both were deemed independent risk factors for osteoporosis \[[@b17-asj-2018-0237]\].

By contrast, Saraykar et al. \[[@b21-asj-2018-0237]\] in 2018 reported no significant difference in BMD between patients taking SSRI and those not at the spine level (*p*=0.275) among elderly women, despite the existing trend for a reduction in BMD at the spine level. This reduction was important only when patients were on both osteoporosis drugs and SSRIs. No difference in T-scores were observed at the spine level (*p*=0.393) \[[@b21-asj-2018-0237]\].

Although each is an independent risk factor for reduced BMD, the treatment of osteoporosis and depression concomitantly requires careful management to avoid induced bone fragility. Therefore, regular monitoring of BMD in long-term treatment is recommended \[[@b17-asj-2018-0237],[@b21-asj-2018-0237]\].

5. Coexisting psychiatric conditions
------------------------------------

Psychiatric conditions, including anxiety and depression, are prevalent in spine patients as a result of chronic pain, disability, and social dependence. Certain subgroups, for example patients with SCI, are particularly prone to depressive symptoms. It is reported that 25%--30% of patients with SCI suffer from MDD \[[@b5-asj-2018-0237]\].

Venlafaxine XR treatment for patients with SCI (\<65 years old) presenting with MDD was examined in two studies in 2015. Fann et al. \[[@b12-asj-2018-0237]\] reported a significant improvement in depressive symptoms by using the Maier subscale in a venlafaxine-treated group compared with a placebo group (1.6 points, *p*=0.02). However, in the study group, no statistically significant difference in the Hamilton Depression Rating Scale (HAM-D) 17 score was observed (*p*=0.42). The Maier subscale was considered to be more sensitive to changes than the HAM-D 17 score, as the former comprises six core items precluding somatic symptoms \[[@b12-asj-2018-0237],[@b30-asj-2018-0237],[@b31-asj-2018-0237]\]. The venlafaxine group also showed significant improvement in SCI-related disability, according to the Sheehan Disability Scale, at 12 weeks (*p*=0.005) \[[@b12-asj-2018-0237]\]. Another study conducted by Richards et al. \[[@b4-asj-2018-0237]\] evaluated nociceptive and neuropathic pain separately with the HAM-D score and Generalized Anxiety Disorder Scale. In patients with neuropathic pain, both scales indicated no significant improvements (*p*=0.815). By contrast, venlafaxine XR led to a statistically significant reduction in patients with nociceptive pain (*p*=0.001) \[[@b4-asj-2018-0237]\]. The drug was well-tolerated by the majority of the patients; however, side effects of blurred vision for the study group and constipation for the placebo group were noted in the two aforementioned studies to be *p*=0.005 and *p*=0.02, respectively \[[@b4-asj-2018-0237],[@b12-asj-2018-0237]\].

6. Cost of spine health care
----------------------------

As spinal surgeries are not uncommon, evaluation of the factors affecting costs is crucial. The mutual association between pain and depression is one of the main causes of poor surgical outcomes and increased cost. A retrospective study performed by Walid and Zaytseva \[[@b18-asj-2018-0237]\] investigated the correlation between antidepressant use and length of hospital stay in terms of cost. Of 578 patients who underwent three common procedures, lumbar microdiscectomy, ACDF, and lumbar decompression and fusion, 24.5% were on antidepressant medication. Depression, which had been determined by antidepressant drug use, was associated with prolonged hospital stays and increased hospital charges, particularly in the lumbar decompression and fusion group (*p*\<0.005). For the lumbar microdiscectomy and ACDF groups, no statistically significant difference was detected. Patients who received antidepressants stayed 1.73 days longer in the hospital and the costs were 14.7% higher than patients not taking antidepressant medication \[[@b18-asj-2018-0237]\].

Another study conducted by Sayadipour et al. \[[@b20-asj-2018-0237]\] in 2016 evaluated 142 patients who underwent elective spine surgery; 41 of the 142 patients were under chronic antidepressant use. Compared with the control group, the total charges were 36% higher, the costs were 22% higher, and the fixed cost was 19% higher among the patients taking antidepressants, who also showed a trend toward a prolonged stay in the hospital. However, none of these factors was statistically significant \[[@b20-asj-2018-0237]\]. Prior to 2010, Sayadipour et al. \[[@b9-asj-2018-0237]\] evaluated the relationship between intraoperative bleeding and antidepressant treatment, concluding that the mean length of hospital stay was approximately 33.3% higher in patients taking antidepressants than in those not (*p*=0.0001).

Conclusions
===========

Antidepressants are used for various purposes in the field of spine surgery: (1) Antidepressants, including amitriptyline and duloxetine, are among the first line drugs to treat neuropathic pain, which is common in patients with degenerative diseases of the spine. Venlafaxine can be used for cases with SCI-related disabilities presenting with depression or nociceptive pain. (2) Preoperative treatment of depression should be considered in patients with intractable spine disease as it may improve patients satisfaction postoperatively by ameliorating postoperative pain and reducing risk of postsurgical delirium and, thus, improving overall QOL.

By contrast, antidepressants may have disadvantages: (1) They may result in prolonged hospital stay and increased cost. (2) SSRIs may increase the risk of intraoperative bleeding up to 2.5-fold and allogenic blood transfusion by 2-fold. Bupropion may also be involved. (3) PFA is warranted preoperatively for major procedures to avoid unexpected significant intraoperative bleeding in patients taking serotonergic antidepressants. (4) The impact of antidepressants on BMD remains controversial; therefore, strict monitoring of BMD in elderly and high-risk group patients is recommended.
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Interventional studies

  Author (year)                                              Drug(s) examined                                                                                                 Objective                                                                                                                                  Relevant result/conclusion                                                                                                                                                                                     Type of study                                                                                                                                                Level of evidence   
  ---------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------- ---------
  Farrokhi et al. \[[@b16-asj-2018-0237]\] (August 2016)     Methylene blue                                                                                                   To examine the effects of MB on postoperative pain and QOL after posterior pedicle screw fixation for thoracolumbar fractures,             \-                                                                                                                                                                                                             Significantly lower VAS in the MB group at 2 months (*p* \<0.001) and 6 months (*p* =0.028).                                                                 HCT                 Level 1
  \-                                                         Significantly lower mean ODI score in the MB group at 2 months (*p* =0.001) and at 6 months (*p* =0.016).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Farrokhi et al. \[[@b13-asj-2018-0237]\] (January 2016)    Methylene blue                                                                                                   To examine the effects of MB on postoperative LBP and QOL after lumbar open discectomy.                                                    \-                                                                                                                                                                                                             Significantly lower VAS scores for LBP in the MB group 24 hours (*p* \<0.001) and 3 months (*p* =0.019).                                                     RCT                 Level 1
  \-                                                         No significant difference on radicular pain scores in both MB and placebo groups (p=0.64).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  \-                                                         Greater reduction in LBP in the MB group (*p* =0.023).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  \-                                                         Significantly improved functional QOL postoperative 3 months in both groups (*p* \<0.001).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Konno et al. \[[@b11-asj-2018-0237]\] (May 2016)           Duloxetine (SNHi)                                                                                                To evaluate the effectiveness and tolerability of duloxetine monotherapy in Japanese patients with CLBP.                                   \-                                                                                                                                                                                                             Duloxetine monotherapy reduced the BPI score of 2 points at week 14 (*p* =0.0010).                                                                           HCT                 Level 1
  \-                                                         No meaningful changes in vital signs, laboratory studies and heart functions are observed with Duloxetine use.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Fann et al. \[[@b12-asj-2018-0237]\] (January 2015)        VenlafaxineXR (SNRI)                                                                                             To evaluate the benefits and tolerability of Venlafaxine XR use in patients suffering from MDD or dysthymic disorder due to chronic SCI.   \-                                                                                                                                                                                                             Improvement on the Maier subscale group (*p* =0.02).                                                                                                         RCT                 Level 1
  \-                                                         No meaningful improvement on HAM-D17-item version (*p* =0.42).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  \-                                                         Less SCI-related disability than placebo on Sheehan Disability Scale (*p* =0.005).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  \-                                                         Venlafaxine XR was well tolerated and effective antidepressant in SCI related disabilities and depression.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Richards et al, \[[@b4-asj-2018-0237]\] (April 2015)       Venlafaxine XR (SNHi)                                                                                            To evaluate the efficacy of Venlafaxine XR in SCI pain and in MDD to show its viability on both neuropathic and nociceptive pain.          Similar HAM-D and GAD-7 scores as placebo on neuropathic pain (*p* =0.815); but statistically and clinically meaningful reductions in nociceptive pain intensity score in Venlafaxine XR group (*p* =0.001).   HCT                                                                                                                                                          Level 1             
  Thomson et al. \[[@b15-asj-2018-0237]\] (January 2009)     Antidepressants                                                                                                  To compare the demographics of patients with FBSS to ones with other painful conditions in the PROCESS trial.                              38% of patients with FBSS were found on antidepressants.                                                                                                                                                       RCT                                                                                                                                                          Level 1             
  Kumar et al. \[[@b14-asj-2018-0237]\] (October 2005)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Cardenas et al. \[[@b10-asj-2018-0237]\] (November 2002)   Amitriptyline (TCA)                                                                                              To investigate the efficacy of Amitriptyline on chronic pain alleviation and pain-related dysfunction improvement in patients with SCI.    \-                                                                                                                                                                                                             No significant change on pain intensity or pain-related disability is observed. (API, SF-MPQ, BPI Pain Interference, CES-Dr, FIM, SWLS, and CHART scales).   HCT                 Level 1
  \-                                                         Findings do not support Amitriptyline use for chronic pain treatment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

MB, methylene blue; QOL, quality of life; VAS, Visual Analog Scale pain score; ODI, Oswestry Disability Index; RCT, randomized controlled trial; LBP, lower back pain; SNRI, serotonin and norepinephrine reuptake inhibitors; CLBP, chronic low back pain; BPI, Brief Pain Inventory; XR, extended release; MDD, major depressive disorder; SCI, spinal cord injury; HAM-D, the Hamilton Depression Rating Scale; GAD-7, General Anxiety Disorder Scale-7; PROCESS, Prospective Randomized Controlled Multicenter Trial of the Effectiveness of Spinal Cord Stimulation; FBSS, failed back surgery syndrome; TCA, tricyclic antidepressant; API, average pain intensity; SF-MPQ, Short Form McGill Pain Questionnaire; CES-Dr, Center for Epidemiologic Studies-Depression Scale; FIM, Functional Independence Measure; SWLS, Satisfaction With Life Scale; CHART, Craig Handicap Assessment and Reporting Techniques.

###### 

Observational studies

  Author (year)                                                                                 Drug(s) examined                                                                                                                                                    Objective                                                                                                                                                                                    Relevant result/conclusion                                                                                                                                               Type of study                                                                                                                                                                                                                                                                                        Level of evidence   
  --------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------- ---------
  Saraykar et al. \[[@b21-asj-2018-0237]\] (2018)                                               SSRI                                                                                                                                                                To measure the association of SSRI with decreased BMD in elderly women \>65 years old.                                                                                                       \-                                                                                                                                                                       No significant difference between SSRI users and nonusers in the BMDs at the lumbar spine (*p* =0.275).                                                                                                                                                                                              CSS                 Level 4
  \-                                                                                            Similar T-scores in two groups at the spine level (*p* =0.393).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Elsamadicy et al. \[[@b7-asj-2018-0237]\] (Apr 2017)                                          SSRI, SNRIs, others                                                                                                                                                 To determine whether depression or receiving antidepressants can be independent risk factors for postoperative delirium in spine deformity patients after spinal surgery                     \-                                                                                                                                                                       Depression is an independent predictor of postoperative delirium after spine surgery in spinal deformity patients (*p* =0.01).                                                                                                                                                                       RCS                 Level 3
  \-                                                                                            No difference between antidepressants users and nonusers in postoperative delirium (*p* =0.56).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Schadler et al. \[[@b8-asj-2018-0237]\] (Feb 2017)                                            SSRI                                                                                                                                                                To detect the association of blood loss and transfusion with one-level spine surgery                                                                                                         SSRI intake is a predictor for: blood loss (34% increase, *p* =0.015); blood transfusion (OR, 4.55; *p* =0.029).                                                         CCS                                                                                                                                                                                                                                                                                                  Level 3             
  Sayadipour et al. \[[@b20-asj-2018-0237]\] (Apr 2016)                                         Antidepressants                                                                                                                                                     To detect the economic effects of antidepressants usage on elective spinal surgery.                                                                                                          36% increase in total charges; 22% increase in cost; 19% increase in fixed cost; but none of the above was statistically significant.                                    CCS                                                                                                                                                                                                                                                                                                  Level 3             
  Robertson et al. \[[@b19-asj-2018-0237]\] (2016)                                              Amitriptyline (GBP+TCA)                                                                                                                                             Evaluating benefits and adverse effects of GBP inclusion to AMP treatment for chronic sciatica                                                                                               GBP inclusion to AMP mono-treatment has showed increased efficacy in terms of VAS reduction (*p* \<0.0001) and ODI reduction (*p* =0.008) scores.                        PCS                                                                                                                                                                                                                                                                                                  Level 2             
  Reduced efficacy measured in patients having adverse effects (VAS, p=0.08; ODI, *p* =0.01).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Sajan et al. \[[@b22-asj-2018-0237]\] (Mar 2016)                                              SSRI                                                                                                                                                                To examine the relationship between SSRI intake and perioperative blood product transfusion in surgical patients with high risk of perioperative bleeding including spinal fusion surgery.   \-                                                                                                                                                                       Increased risk of exposure to allogeneic hemostatic blood products (OR, 2.2; CI, 1.2--3.98).                                                                                                                                                                                                         PCS                 Level 2
  \-                                                                                            No effect modification was found between SSRI use and surgery type, age, sex, or concurrent antiplatelet therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Elsamadicy et al. \[[@b6-asj-2018-0237]\] (2016)                                              Antidepressants (not specified)                                                                                                                                     To detect the association between treating depression before cervical spine surgery and patient satisfaction.                                                                                No difference at postoperative years (1 and 2) between antidepressants users and nonusers in terms of neck pain VAS, NDI, SF-12 PCS, and SF-12 mental component score.   RCS                                                                                                                                                                                                                                                                                                  Level 3             
  Rauma et al. \[[@b17-asj-2018-0237]\] (Apr 2015)                                              SSRI, SNRI, TCA                                                                                                                                                     To detect the association of major depressive disorder and antidepressants use with bone mineral density in men.                                                                             Recurrent MDD was associated with lower spinal BMD (-4%)                                                                                                                 CSS                                                                                                                                                                                                                                                                                                  Level 4             
  Sayadipour et al. \[[@b9-asj-2018-0237]\] (Jan 2012)                                          SSRI, SNRI, TCA                                                                                                                                                     To determine if antidepressants usage can be associated with increased bleeding at elective spinal surgery,                                                                                  \-                                                                                                                                                                       Patients on antidepressants: 23% more blood loss (*p*=0.01); 2.5 times greater loss than the matched control group measured in anterior/posterior lumbar fusions operations; 33.3% longer hospital stay (1 day more, *p* =0.0001); SSRI/SNRI showed higher blood loss (832 mL increase, *p* =0.01)   CCS                 Level 3
  \-                                                                                            PLF group: higher blood loss (*p* =0.032); higher blood loss in patients taking Bupropion (708 mL, *p* =0.023); longer hospital stay (0.8 days more, *p* =0.0004)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Walid etal. \[[@b18-asj-2018-0237]\] (2010)                                                   Antidepressants (not specified)                                                                                                                                     To measure the prevalence and impact of mood altering medications and opioids in patients undergoing spine surgery on hospital cost.                                                         25.4% of spine surgery patients were on antidepressants showing (*p* \<0.05) in both: longer hospital stay; higher hospital cost                                         CSS                                                                                                                                                                                                                                                                                                  Level 4             

SSRI, selective serotonin reuptake inhibitors; BMD, bone mineral density; CSS, cross sectional study; SNRI, serotonin and norepinephrine reuptake inhibitors; RCS, retrospective cohort study; OR, odds ratio; CCS, case control study; GBP, gabapentin; TCA, tricyclic antidepressant; AMP, amitriptyline; VAS, Visual Analog Scale pain score; ODI, Oswestry Disability Index; PCS, prospective cohort study; CI, confidence interval; NDI, Neck Disability Index; SF-12, Short Form-12; PCS, Physical Component Score; MDD, major depressive disorder; PLF, posterior lumbar fusion.
